Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

2022 2021 2020 2019 2018 2017 2016 2015 2014

Home > ABOUT SIMR > Milestones > 2021

2021

18 2022-11

In December, SR419, the Company's first innovative drug to e

In December, SR419, the Company's first innovative drug to enter the clinical stage, was approved by the US Food and Drug Administration (FDA) for its international multi-center Phase II clinical ...
18 2022-11

In October, it completed the B+ round financing of nearly RM

In October, it completed the B+ round financing of nearly RMB200 million led by Zhang Jiang Haocheng and Zhang Jiang Haoheng...
18 2022-11

In October, the second drug candidate, SR1375, successfully

In October, the second drug candidate, SR1375, successfully completed its first dose group administration in Australia....
18 2022-11

In July, the China IND application for SR419, SIMR Biotech's

In July, the China IND application for SR419, SIMR Biotech's first analgesic candidate, was approved by the implied license...
18 2022-11

In February,SIMR Biotech Advisory Board (SAB) was establishe

In February,SIMR Biotech Advisory Board (SAB) was established with the appointment of four internationally well-knowed pain experts....

Road 1 page 5 strip

Road 1 page 5 strip